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Introduction: A liver abscess in Crohn’s disease is a rare but important entity that is associated with a poor
prognosis and high mortality when treatment is delayed. We report a case of successful liver segmentectomy for a
methicillin-resistant Staphylococcus aureus liver abscess in a patient with Crohn’s disease under infliximab treatment.
Case presentation: A 31-year-old Japanese man, who had been treated with infliximab infusions for Crohn’s
disease, was referred to our hospital presenting with an abrupt onset of high fever and an elevated white blood
cell count and serum C-reactive protein level. Computed tomography revealed a liver abscess occupying segment
8. The limited effect of percutaneous transhepatic abscess drainage and antibiotics led us to perform radical
resection of the abscess. The patient recovered quickly after surgery and the postoperative course was uneventful.
Conclusion: The present case suggests that surgical removal of an abscess should be considered for patients under
immunosuppression or refractory to conventional treatment.Introduction
Infliximab treatment has recently emerged as a safe and ef-
fective method of inducing and maintaining remission of
Crohn’s disease [1-3], but the immunosuppression some-
times results in unexpected complications, such as infection
with Mycobacterium tuberculosis, sepsis, severe pneumonia,
severe liver dysfunction, and leucopenia. Among the poten-
tial complications, a liver abscess is critical, with a higher
incidence than that in the general population (114 to 297
per 100,000) [4].
Here, we report a case of a large solitary methicillin-
resistant Staphylococcus aureus (MRSA) liver abscess loca-
lized in Couinaud’s segment 8 in a patient with Crohn’s
disease under infliximab treatment, which was successfully
resected and cured by anatomic liver resection following
medical and interventional treatment failure.* Correspondence: yasusuga-tky@umin.net
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A 31-year-old Japanese man undergoing infliximab treat-
ment for Crohn’s disease was admitted to our hospital
with high fever and pain in the right upper abdominal
region. He was diagnosed with Crohn’s disease 15 years
ago when he had presented with an anal fistula, which
was stable without resistant abscess for five years. Due
to gradual exacerbation of the disease, he underwent an
ileocecal resection with an ileostomy, and subsequent
abscess drainage around the stoma 10 years ago. A second
operation for ileal stenosis was performed with a partial
ileum resection and a new ileostomy six years before the
admission. He had not been treated with methylpredniso-
lone, but underwent infliximab treatment two years before
the admission to induce remission because of further
exacerbation of the disease. Infliximab (five mg/kg) was
administered every eight weeks for nine times, successfully
suppressing the disease. The last infusion of infliximab was
administered two months before referral to our department.
On admission, his mean arterial pressure, heart rate,
body temperature, and respiratory rate were 76mmHg,
78/minute, 39.3°C, and 16/minute, respectively. Afterl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, his circulatory and respiratory condition was stable
without vasopressor treatment or oxygen administra-
tion. Laboratory data revealed severe inflammation with
a white blood cell count of 20400/μL with 80% neutro-
phils, a serum C-reactive protein level of 25.0mg/dL, a
serum fibrin degradation products level of 26μg/mL,
and a serum D-dimer level of 11.6μg/mL. His liver func-
tion was slightly impaired with increased aspartate and
alanine aminotransferase levels (87IU/L and 149IU/L,
respectively); however, no other organ impairment was
observed. The results of the arterial blood culture and
serum anti-ameba shigella dysenteriae antibody tests were
negative. Abdominal ultrasonography and abdominal com-
puted tomography on admission revealed a huge heteroge-
neous lesion in the liver, 50mm in diameter, occupying
Couinaud’s segment 8 (Figure 1A).
An eight-French scale (Fr) percutaneous transhepatic
abscess drainage (PTAD) tube was inserted and the pa-
tient received intravenous sulbactam sodium and cefoper-
azone sodium (four g/day) and subsequent meropenem
(four g/day). The first microbial culture of the pus that
drained from the PTAD revealed MRSA and Escherichia
coli. MRSA was confirmed in MRSA screening agar. The
minimum inhibitory concentration of vancomycin was one
mg/L. Therefore vancomycin (one g/day) was started and
continued for eight days, but the patient’s fever and labora-
tory and radiographic findings did not improve (Figures 1B
and 1C). Vancomycin was then changed to teicoplanin
with an initial dose of 400mg/day and a maintenance dose
of 200mg/day maintaining the target trough level at 11 to
13μg/mL. Additional interventional treatment with place-
ment of another larger (12Fr) PTAD tube was performed,
which failed to relieve the liver abscess, and the size of
the abscess increased to 60mm in diameter on the follow-
up computed tomography scan (Figure 1C). During the
course, additional blood cultures were taken twice and an
abscess culture was performed which resulted negative for
bacteremia but positive for MRSA abscess. Without any
improvement in the patient’s general condition and clin-
ical findings after seven days of teicoplanin treatmentFigure 1 Computed tomography images of the lesion. A) Cystic hetero
liquefied component. B) Axial images showing a rim-enhancing lesion sug
treatment. C) Axial images showing a rim-enhancing lesion suggestive of r
teicoplanin treatment.with additional interventional treatments, we decided to
perform urgent radical resection of the abscess. Under
general anesthesia, a liver resection of segment 8 was
performed through an inverted T-shaped incision on day
30 after admission.
Meticulous guidance by intraoperative ultrasonography
allowed us resection of segment 8 without exposing the ab-
scess cavity. The operating time and intra-operative blood
loss were 510 minutes and 900mL, respectively. A patho-
logic examination revealed a liver abscess, 65×45×36mm
in size, weighing 200g, composed of irregular necrosis
with epithelioid and fibrotic formations in a surrounding
palisading pattern (Figure 2). The patient’s temperature
returned to normal and the laboratory data also normal-
ized immediately after the operation. The patient received
intravenous teicoplanin and meropenem for seven more
days after surgery. After that, 500mg/day of ciprofloxacin
was administered orally. The postoperative course was
uneventful, except for intravenous hyperalimentation
catheter-related Candida parapsilosis, which was success-
fully treated with fluconazole. The patient was discharged
on postoperative day 41. The treatment course of the
patient is summarized in Figure 3 with the changes in the
laboratory data. So far, no evidence of recurrent liver
abscess or Crohn’s disease progression has been observed
in the four months after the resection, with oral adminis-
tration of three g/day of PENTASAW (mesalamine) and
500mg/day of ciprofloxacin.
Discussion
Pyogenic liver abscess (PLA) is uncommon with an inci-
dence of 0.5% to 0.8%, accounting for 15 per 100,000
hospital admissions, but it is an important entity due to
the potential lethality [5]. Currently, the most common
cause of PLA is biliary tract disease, including cholelithia-
sis, benign and/or malignant biliary strictures, and con-
genital anomalies of the biliary tree, reported to account
for 37% of cases [6,7]. Appendicitis, diverticulitis, inflam-
matory bowel disease, and perforated hollow viscera are
possible sources of septic emboli. Hematogenous dissem-
ination of causative organisms in association with systemicgeneous lesion in segment 8 of the right liver lobe, with a partly
gestive of residual liver abscess after drainage and vancomycin
esidual liver abscess after drainage with a larger tube and
Figure 2 Resected portion of the liver demonstrating liver abscess, which was positive for methicillin-resistant Staphylococcus aureus
on culture.
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ritis, is a rare cause of PLA. The bacteriology of a PLA
is polymicrobial, with Klebsiella, group D Streptococcus,
E. coli, and Bacteroides. Although recovery of S. aureus
from PLA with conservative therapy occurs in approxi-
mately 4% of cases, that of MRSA is rare [6].
Inflammatory bowel diseases, including Crohn’s disease,
are associated with frequent portal venous bacteremia dueFigure 3 Clinical course with changes in the laboratory data. Abbrevia
PTAD, percutaneous transhepatic abscess drainage; SBT/CPZ, sulbactam sod
cell counts; CRP, C-reactive protein.to disruption of the bowel barrier, which easily results in bac-
terial translocation [8]. In addition, the well-known compli-
cations of Crohn’s disease, such as fistulization, perforation,
and intra-abdominal abscess formation could predispose
patients to the development of microbial invasion of the
portal venous system and seeding of the hepatic paren-
chyma [9]. Thus, Crohn’s disease is associated with various
hepatobiliary disorders, including pericholangitis, sclerosingtions: CLDM, clindamycin; CPFX, ciprofloxacin; MEPM, meropenem;
ium and cefoperazone sodium; TEIC, teicoplanin; WBC, white blood
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but the development of PLA is rare, with only 47 reported
cases in the English literature [8,9,11-13]. Many authors
have pointed out that not only bowel inflammation itself
but also treatment with steroids or infliximab, malnutrition,
and the underlying immunologic impairment of patients
with Crohn’s disease might have a role in developing PLA.
To the best of our knowledge, this is the first report of a
MRSA liver abscess developing in a patient with Crohn’s
disease under infliximab treatment. In this particular case,
the Crohn’s disease itself was well suppressed with suc-
cessful remission induced after nine infusions of inflixi-
mab. In addition, a colon and intestinal examination before
discharge revealed almost normal mucosa without any
symptoms. It is also well-accepted that an immunocom-
promised condition plays a critical role in developing PLA
[5,14]. All these findings led us to speculate that the im-
munosuppressive state under infliximab treatment might
have played a critical role in the development of the MRSA
liver abscess in the present case, considering the documen-
ted association between cytokine inhibition by infliximab
and infection [13,15-17].
Systemic parenteral antimicrobial therapy with broad
spectrum antibiotics remains the mainstay primary treat-
ment of PLA. The regimen must be altered to target spe-
cific organisms isolated from the abscess aspirate [5]. An
abscess larger than three cm in diameter is generally
required to be drained [17]. The image-guided percutan-
eous technique is a standard treatment of drainage [7].
Nevertheless, there remains a role for open or laparoscopic
surgical intervention in the management of PLA with the
documented indication as follows: no clinical response
after four to seven days of percutaneous drainage; mul-
tiple, large, or loculated abscess; thick-walled abscess with
viscous pus; and concomitant intra-abdominal surgical
pathology [5,16,18,19]. Some authors have reported the
efficacy and safety of emergent surgical drainage or
resection [9,10,14,20,21].
Because of its rarity, it is unclear whether PLA caused
by S. aureus (or MRSA) follows a different or more severe
clinical course than PLA caused by enteric flora. The
aggressive nature of the present PLA might validate the
decision to perform surgery. Considering that few cases
of surgical resection of PLA [15] have been reported, the
necessity of anatomic resection of PLA including the sur-
rounding parenchyma might be a matter of debate, but
the satisfactory course of the present case after resection
justifies our decision.
However, there were some critical flaws in our man-
agement of this case. First, an expert panel has recently
recommended the selection of daptomycin or linezolid as
a second- or even first-line treatment for serious MRSA
infection [22]. Considering that the crucial points for the
treatment of a patient with severe infection are promptresuscitation management, adequate source control, and
proper antibiotic therapy, the way we selected the anti-
biotic could be criticized as inappropriate in this case.
Second, the operative procedure, anatomic segment 8
resection, took too long, which might have burdened some
unnecessary stress on the patient. Yet, we would still like
to emphasize that the conversion to surgical removal with-
out delay seems crucial in a case with a complicated severe
abscess as in the present patient.
Conclusion
Here we reported a case of a MRSA liver abscess in a pa-
tient under infliximab treatment for Crohn’s disease. Resec-
tion of a liver abscess could be an option for refractory PLA.
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